A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|Millennium Pharmaceuticals, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
The main purpose of this research study is to investigate if a drug called Vedolizumab is safe and effective in preventing acute graft-versus-host disease (attack of donor cells on recipient healthy organs after transplant) of the gut in comparison to placebo (dummy drug). This will be studied in patients undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) from an unrelated donor for a blood cancer such as acute leukemia, chronic myelogenous leukemia, myelo fibrosis, or other myeloproliferative disorder.
This study is closed
Ran Reshef, MD
|Are you 18 years of age or older?
|Have you been diagnosed with leukemia, myelofibrosis, or other myeloproliferative disorder?